Precigen to present plans for realizing commercial vision for prgn-2012 at the 43rd annual j.p. morgan healthcare conference

–   prgn-2012 has potential to be first fda-approved therapeutic for treatment of rrp, a rare and devastating chronic disease  – –   company completed bla submission for prgn-2012 for treatment of adults with rrp  – –   commercial readiness activities underway in anticipation of potential launch of prgn-2012; company started 2025 with approximately $100 million cash on-hand* with cash runway well into 2026, beyond the anticipated launch in the second half of 2025  – –   according to recently updated internal analysis derived from review of claims data, the market opportunity for prgn-2012 in rrp is estimated to be approximately 27,000 adult patients in the us  – –   immense market potential for adenoverse platform in other hpv6/11-driven indications, such as genital warts, which has significant unmet need with annual global incidence of more than 4 million and prevalence of more than 25 million, and hpv16/18-driven indications, such as cervical cancer and head and neck cancers  – –   company presentation on thursday, january 16, 2025 at 9:00 am pt in san francisco – germantown, md. , jan. 13, 2025 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced highlights for the upcoming company presentation at the 43rd annual j.p.
PGEN Ratings Summary
PGEN Quant Ranking